DHANUKA Laboratories Ltd.

CIN No.: U24100DL1993PLC052285

Unit-I: 7th Km.Old Manesar Road, Village Mohammedpur, Gurgaon - 122004 Haryana, (INDIA)
Phone : +91 124 4848900 Fax: +91 124 4848999 Email: dll@dhanuka.com Website: www.dhanukalab.com
Unit-II: Plot No. SP4-4, Industrial Area, Keshwana Rajput, Kotputli, Shahpura, Distt. Jaipur-303108 (Rajasthan) INDIA

June 01, 2020

The Manager **Listing Department** **BSE Limited** **Phiroze Jeejeebhoy Towers** **Dalal Street, Mumbai- 400 001** **Scrip Code: 524372**	**The Manager** **Listing Department** **National Stock Exchange of India Limited** **Exchange Plaza, 5th Floor** **Plot No. C/1, G Block, Bandra Kurla Complex,Bandra-East** **Mumbai- 400 051** **SYMBOL: ORCHIDPHAR**

Sub: Disclosure under Regulation 31(4) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulation, 2011

Dear Sir/Madam

With reference to the captioned subject, we would like to inform you that as per Resolution plan approved for M/s. Orchid Pharma Limited, M/s. Dhanuka Laboratories Limited ("Resolution Applicant") has been allotted 4,00,00,072 equity shares (10,000 Equity shares pursuant to Scheme of Amalgamation on March 30,2020 and 3,99,90,072 equity shares of Rs.10/- on March 31,2020 on Preferential basis) of Orchid Pharma Limited. The Company has made necessary applications to the Stock exchanges in this regard and the approval for the same is awaited. Basis receipt of the approval from the exchanges the company will make applications to the Stock exchange(s) for reclassification of M/s. Dhanuka Laboratories Limited under the "Promoter" Category as per approved Resolution plan.

Pursuant to the provisions of Regulation 31(4) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, we hereby declare that the above Promoters and the members of Promoter Group including Persons acting in concert have not made any encumbrance of shares, directly or indirectly during the Financial Year ended March 31, 2020.

Kindly take the above disclosure on your records.

Thanking you

Yours sincerely

For **Dhanuka Laboratories Limited**

Manish Dhanuka
Managing Director

Copy to:
(1)Members of the Audit Committee-Orchid Pharma Limited
(2)The Company Secretary-Orchid Pharma Limited

June 01, 2020

The Manager **Listing Department** **BSE Limited** **Phiroze Jeejeebhoy Towers** **Dalal Street, Mumbai- 400 001** **Scrip Code: 524372**	**The Manager** **Listing Department** **National Stock Exchange of India Limited** **Exchange Plaza, 5th Floor** **Plot No. C/1, G Block, Bandra Kurla Complex,** **Bandra-East** **Mumbai- 400 051** **SYMBOL: ORCHIDPHAR**

Sub: Disclosure under Regulation 31(4) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulation, 2011

Dear Sir/Madam

Pursuant to the provisions of Regulation 31(4) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, we hereby declare that the Promoters and the members of Promoter Group including Persons acting in concert have not made any encumbrance of shares, directly or indirectly during the Financial Year ended March 31, 2020.

Kindly take the above disclosure on your records.

Thanking you

Yours sincerely

For and on behalf of Promoter, Promoter Group and PAC

MANISH DHANUKA
PROMOTER

Copy to:
(1)Members of the Audit Committee-Orchid Pharma Limited
(2)The Company Secretary-Orchid Pharma Limited